Combining CRISPR/Cas9 with barcoding has been used to track the clonal dynamics of lung cancer cells during their acquired resistance to EGFR inhibitors and subsequent response to combined drug therapies163, 164. The gene discussed is EGFR; the disease is lung carcinoma.